Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01676584 · ClinicalTrials.gov registry record · Phase 1
A Study of Single Dose RO6811135 in Healthy Volunteers
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT01676584 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 56 participants.
The verdict
NCT01676584, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6811135 in healthy volunteers. Subjects will be randomized in cohorts to receive either single ascending doses of RO6811135 or placebo subcutaneously.
Interventions
- DRUG placebo
- DRUG RO6811135
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2012-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01676584
The ClinicalTrials.gov registry entry for NCT01676584 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01676584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01676584 about?
NCT01676584 is a clinical study titled "A Study of Single Dose RO6811135 in Healthy Volunteers". This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6811135 in healthy volunteers. Subjects will be randomized in cohorts to receive either single ascending doses of RO6811135 or placebo subcutaneously.
What is the current status of trial NCT01676584?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2012-09. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01676584?
The interventions under investigation include: placebo (DRUG), RO6811135 (DRUG).
Who is sponsoring clinical trial NCT01676584?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.